Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for preventing and treating coronary heart diseases and preparation method of drug

A drug and pharmacy technology, applied in the field of medicinal chemistry, can solve the problem of ineffective treatment of coronary heart disease, etc., and achieve the effect of excellent LCAT activation effect, increase HDL level, and excellent activation effect

Active Publication Date: 2018-11-09
MUDANJIANG MEDICAL UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs help improve certain risk factors for coronary heart disease, such as regulating blood pressure or lowering lipid or glucose levels in the blood, but they are still not effective in treating coronary heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for preventing and treating coronary heart diseases and preparation method of drug
  • Drug for preventing and treating coronary heart diseases and preparation method of drug
  • Drug for preventing and treating coronary heart diseases and preparation method of drug

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0045] The present invention also provides a preparation method of the compound of formula I, the preparation method comprising the following steps:

[0046] Reaction of a compound of formula II with a compound of formula III in the presence of a base to prepare a compound of formula I

[0047]

[0048] Among them, R 1 -R 7 as defined herein;

[0049] The base is selected from organic bases such as triethylamine or pyridine; or inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate.

[0050] The present invention also relates to a pharmaceutical composition comprising at least one of said compounds or pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof as an active ingredient. The pharmaceutical composition may comprise a pharmaceutically acceptable carrier or excipient.

[0051] The pharmaceutical composition can be prepared according to methods known in the art. Any dosage form su...

Embodiment 1

[0062] Example 1: (Z)-6-((6-methyl-2-oxoindole-3-methylene)methyl)-4-oxospiro[chroman-2,4'-piperidine ]-1'-tert-butyl formate (compound SP-1)

[0063]

[0064] Put tert-butyl 6-formyl-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate (10.0mmol) into the flask, add 100m absolute ethanol to dissolve it, and then Then 6-methylindolin-2-one (10.0 mmol) and 2 ml of triethylamine were added, and the reaction was stirred at room temperature for 3 h, and a large amount of precipitation appeared. Suction filtration under reduced pressure, the filter cake was washed with a small amount of absolute ethanol, and dried under vacuum to obtain 4.34 g of the title product as a white solid, with a yield of 91.5%.

[0065] ESI-MS: 475.22[M+H] +

[0066] Elemental analysis: theoretical value C, 70.87; H, 6.37; N, 5.90; O, 16.86

[0067] Found value C, 70.58; H, 6.55; N, 5.79; O, 17.08

[0068] 1 H NMR (400MHz, CDCl 3 )δ11.08(s,1H),7.85(d,1H),7.70(s,1H),7.51(d,1H),7.39(d,1H),7.13(s,1H)...

Embodiment 2

[0069] Example 2: (Z)-6-((5,6-dimethoxy-2-oxoindoline-3-methylene)methyl)spiro[chroman-2,4'-piperidine ]-4-one (SP-2)

[0070]

[0071] According to the method of Example 1, replace 6-formyl-4-oxospiro[chroman-2,4'-piperidine]-6-carbaldehyde with 4-oxospiro[chroman-2,4'-piperidine Pyridine]-1'-carboxylic acid tert-butyl ester, substituting 5,6-dimethoxyindolin-2-one for 6-methylindolin-2-one afforded the title compound as a gray solid, yield 87.9 %.

[0072] ESI-MS: 423.18[M+H] +

[0073] Elemental analysis: theoretical value C, 68.23; H, 6.20; N, 6.63; O, 18.94

[0074] Found value C, 68.35; H, 6.02; N, 6.97; O, 18.66

[0075] 1 H NMR (400MHz, CDCl 3 )δ11.10(s,1H),7.88(d,1H),7.53(s,1H),7.29(s,1H),7.22(s,1H),7.10(d,1H),6.89(d,1H ), 3.85(s,6H), 2.85(t,4H), 2.66(s,2H), 2.02(s,1H), 1.91(t,4H).

[0076] According to a method similar to Example 1, the following compounds were synthesized:

[0077]

[0078] Example of efficacy

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an indolinone derivative or pharmaceutically acceptable salt, stereisomer, tautomer, solvate and predrug thereof. The compound disclosed by the invention has an excellent LCATactivation effect, is capable of remarkably increasing the HDL level and therefore can be used as an effective component in a treating agent or a prevention agent for coronary heart diseases (including heart failure, myocardial infarction, angina pectoris, myocardial ischemia, cardiovascular disorders and angiogenic restenosis), arteriosclerosis, arteriosclerotic heart disease, cerebrovascular diseases (including stroke and cerebral infarction), peripheral blood vessel diseases (including diabetic vascular complications), dyslipidemia, low HDL cholesteremia, high LDL cholesteremia or kidney diseases.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, specifically, the invention relates to a medicine capable of effectively activating lecithin-cholesterol acetyltransferase (LCAT), and the invention also relates to a preparation method of the medicine. Background technique [0002] Coronary atherosclerotic heart disease is a heart disease caused by atherosclerotic lesions in the coronary arteries that cause stenosis or blockage of the vessel lumen, resulting in myocardial ischemia, hypoxia or necrosis. It is often called "coronary heart disease". However, the scope of coronary heart disease may be wider, including inflammation, embolism, etc. leading to stenosis or occlusion of the lumen. The World Health Organization divides coronary heart disease into five categories: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease) and sudden death. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/107A61K31/438A61K31/4427A61P9/00A61P9/10
CPCA61P9/00A61P9/10C07D491/107
Inventor 孔娟唐玉立侯丽媛杨超马小升金涛
Owner MUDANJIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com